MAPT and Alzheimer disease: We did not observe differences in the levels of core AD CSF biomarkers in patients with CMBs compared to patients without CMBs or depending on their location for amyloid (lobar: 507.72 pg/mL (209.55) vs. nonlobar: 609.89 pg/mL (200.09); p = 0.447), total tau (lobar: 526.54 pg/mL (294.07) vs. nonlobar: 529.11 pg/mL (320.32); p = 0.616) or tau pathology (lobar: 85.66 pg/mL (39.53) vs. nonlobar: 73.24 pg/mL (31.98); p = 0.585).